Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3269765

CCCCNC(=O)Nc1ccc(Oc2ccc(-c3c[nH]c(COc4ccccc4)n3)cc2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HTT P42858 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ROCK2 O75116 2/20 0.41
EPHX1 P07099 4/20 0.40
PPARA Q07869 1/20 0.40
KDR P35968 1/20 0.40
EPHX2 P34913 1/20 0.39
CDK8 P49336 1/20 0.38
KIT P10721 1/20 0.38
PDGFRA P16234 1/20 0.38
DDX3X O00571 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3278196 0.95 KMT2A (0.47) KMT2AALDH1A1HTTGAAMAPT
Trifluoroacetic Acid SCHEMBL3270278 0.92 MTNR1B (0.45) MAPTKDREPHX2HDAC3HDAC4
SCHEMBL3281277 0.86 MTNR1B (0.49) MAPTROCK2KDREPHX2
Trifluoroacetic Acid SCHEMBL8216241 0.84 HDAC3 (0.40) KMT2AALDH1A1HTTMAPTPPARA
Trifluoroacetic Acid SCHEMBL4460353 0.84 MCL1 (0.47) PPARAHDAC3HDAC4HDAC1HDAC7
SCHEMBL3269527 0.83 ALOX5 (0.50) KMT2AROCK2PPARAKDREPHX2
SCHEMBL3269768 0.82 MAPT (0.38) ALDH1A1HTTMAPTHDAC3HDAC4
SCHEMBL3275815 0.81 GBA1 (0.46) KMT2AALDH1A1KDREPHX2CDK8
SCHEMBL4457369 0.80 MEN1 (0.48) KMT2AALDH1A1HTTMAPTNPSR1
SCHEMBL3270529 0.80 MAPK1 (0.47) ALDH1A1HTTROCK2PPARAEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2024335-B1 NOVEL IMIDAZOLE DERIVATIVES, PREPARATION AND USER THEREOF AS MEDICINE IPSEN PHARMA (FR) 2010-06-23 EP claimed
US-20090186930-A1 NOVEL IMIDAZOLE DERIVATIVES, PREPARATION AND USER THEREOF AS MEDICINE SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-07-23 US claimed
US-8188133-B2 Imidazole derivatives, preparation and user thereof as medicine IPSEN PHARMA S.A.S. (FR) 2012-05-29 US disclosed
US-20090186930-A1 NOVEL IMIDAZOLE DERIVATIVES, PREPARATION AND USER THEREOF AS MEDICINE SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186930-A1 NOVEL IMIDAZOLE DERIVATIVES, PREPARATION AND USER THEREOF AS MEDICINE CYP51A1, IKZF3, MIF KMT2A 1928/4885ALDH1A1 776/4885HTT 4815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.